lanzaxinvestorpresentati

Accelerating the path to scale and commercialization of globally sought-after synthetic biology strains LanzaX Nasdaq: LNZA Dedicated Strain Innovation +

This presentation includes forward-looking statements regarding, among other things, the plans, strategies, and prospects, both business and financial, of LanzaTech. These statements are based on the beliefs, assumptions, projections and conclusions of LanzaTech’s management. Forward-looking statements are inherently subject to risks, uncertainties and assumptions, many of which are outside LanzaTech’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. LanzaTech cannot assure you that it will achieve or realize these plans, intentions or expectations. Forward-looking statements are not guarantees of future performance, conditions or results, and you should not rely on forward-looking statements. Generally, statements that are not historical facts, including those concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates,” “intends” or similar expressions. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to scale and develop the LanzaX business to the maturity and levels of efficiency required to realize returns, or to receive the required government and regulatory approvals for the marketing and sale of LanzaX; timing delays in the advancement of projects to the final investment decision stage or into construction; failure by customers to adopt new technologies and platforms; fluctuations in the availability and cost of waste feedstocks and other process inputs; the availability and continuation of government funding and support; broader economic conditions, including inflation, interest rates, supply chain disruptions, employment conditions, and competitive pressures; unforeseen technical, regulatory, or commercial challenges in scaling proprietary technologies, business functions or operational disruptions; and other economic, business, or competitive factors, and other risks and uncertainties, including the risk factors and other information contained in LanzaTech’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, as well as other existing and future filings with the U.S. Securities and Exchange Commission. Any forward-looking statement herein is based only on information currently available to LanzaTech and speaks only as of the date on which it is made. LanzaTech undertakes no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This presentation may include data obtained from third-party studies that the company has not independently verified. Forward-looking information obtained from these sources is subject to the same qualification and the additional uncertainties regarding the other forward- looking statements in this presentation. The use or display of third parties’ trademarks, service marks, trade name or products in this presentation, if any, is not intended to, and does not imply, a relationship with us, or an endorsement or sponsorship by or of LanzaTech. The trademarks, service marks and trade names referred to in this presentation may or may not appear with the TM or SM symbols, but such references or the absence of such references are not intended to indicate, in any way, that LanzaTech or any third party will not assert, to the fullest extent permitted under applicable law, their rights in respect thereof. DISCLAIMER

3 and other shareholders 50 % Tharsis Capital and other shareholders to contribute cash sufficient for the joint venture to reach profitability; Tharsis Capital brings deep experience in chemicals and sustainable technology sectors and will be a valued collaborative partner LanzaTech contributes license to synthetic biology and strain engineering (synbio) related intellectual property (IP), staff, and capabilities and a roster of joint development agreements and contract research projects LanzaX Joint Venture 50 % LanzaX LanzaTech intends to spin out its synthetic biology and strain engineering platform into a growth-oriented joint venture to access capital needed to accelerate its existing development pipeline of projects, including acetone, isopropanol, and high-value specialty products A Commercial Launchpad for Sustainable Chemical Production

LanzaX is designed to take the reins on existing and future research and development projects, enabling LanzaTech to focus on high-impact commercial growth priorities of its core biorefining platform, including increasing opportunities in sustainable aviation fuel production (SAF) 4 Symbiotic Relationship with LanzaTech Joint Venture LanzaX LanzaTech to contribute existing contracts with global firms, leading brands, government agencies, and universities, along with over 100 demonstrated molecules LanzaX to leverage proven commercial expertise of LanzaTech in scaling ethanol production to scale new molecules quickly LanzaX LanzaX to specialize in the design, development, optimization, and validation of gas fermentation strains Focused expertise in strain innovation designed to expand LanzaTech’s gas fermentation capabilities and industry sector reach Ability to leverage LanzaTech’s existing bioreactors to accelerate path to commercialization Strain Innovation by LanzaX to Drive LanzaTech’s Gas Fermentation Capabilities to New Heights

5 Compelling Total Addressable Market Spanning Multiple VerticalsLanzaX P ro d u ct V al u e Market Size $200M $50B $500/MT $5,000/MT Packaging Rubber Solvents Fragrances Specialty Chemicals LanzaX has the potential to be a transformational biomanufacturing platform that leverages dedicated capital and a team with deep expertise to fast track the development of an existing portfolio of near-commercial molecules in biochemicals, biomaterials, and a broad range of chemical specialties, that access numerous sizable industries looking for the types of strain innovation LanzaX offers

Value proposition: Value creation from product sales while reducing emissions LanzaX *JDA- Joint Development Agreements Revenue Model – Driving Profitable Growth Delivers Research and New Microbes Unique Strain Innovation $ $ CUSTOMERS Global brands, Government Agencies, and Universities LanzaX JDA* and Contract Research Off-Take Microbe Product Sales Off-take with minimal capital outlay: Leveraging existing LanzaTech expertise and infrastructure Accelerated Project Development: Leverage existing flexible microbe strains to tailor to specific customer needs Value proposition: Provide specialized research and microbe off-takes Commercial Production CUSTOMERS Industrial partners, heavy industry Revenue Streams ✓ Project revenue ✓ Product sales ✓ Licensing revenue ✓ Profit-sharing in facility results ✓ Operating and managing facilities Product sale revenue: Through increasingly higher-value products Driving product demand: Through product diversification $ LanzaX creates value for LanzaTech via: Biorefining facilities that license LanzaTech biorefining technology

7 Competitive EdgeLanzaX Uniquely Positioned Over Competitors Most advanced synthetic biology platform for C1 microbes and partnership with LanzaTech provides powerful path to scale Capabilities: Service Model Organism Portfolio Biofoundry Gas Handling Scale Up C1 Microbes Sugar Microbes FungiYes Yes Proven path to commercial scale through LanzaTech LanzaX No dedicated internal scale-up No Sugar Microbes Fungi No C1 Microbes Organism Companies, e.g. Biomanufacturing Companies, e.g. Gas Fermentation Companies, e.g. Yes Yes No Yes Yes Yes Yes No No No

8 CapabilitiesLanzaX ✓ Leading synthetic biology platform for C1 microbes ✓ State-of-the art strain modeling, AI, and synthetic biology capabilities across full design-build-test-learn cycle ✓ Building on 15+ years of genetic tool development and optimization of continuous, gas fermentation organisms ✓ World-first biofoundry for automated strain engineering of gas fermentation organisms ✓ Comprehensive gas fermentation knowledge base

9 TeamLanzaX Projected annual cost reduction of ~$8 million to LanzaTech, primarily driven by employee transfer to LanzaX CEO Strain Design & Modeling Strain Validation & Fermentation Commercialization & Business Development Science & Innovation Advisors Support Functions ▪ LanzaTech to transfer over 30 talented and experienced employees to LanzaX: → Aggregate years of experience: 250+ → Number of doctorates: 10+ PhD (Molecular Biology, Microbiology, Biotechnology, Bioengineering, Chemical Engineering, Computational Biology) → Number of publications: 200+ → Number of patents: 600+ Search to commence for new CEO of LanzaX

Investor contact: Kate Walsh VP Investor Relations [email protected]